Brain cancers are among the most difficult to treat, as Tocagen's struggles follow late-stage study failures earlier this month from AbbVie and Bristol-Myers Squibb.
The...
Array's combination of Braftovi (encorafenib) and Mektovi (binimetinib) already appears well received in the small clinical setting of advanced melanoma with BRAF V600E or...
Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy.
Novartis and Roche have recognized this with their...
Zolgensma (onasemnogene abeparvovec) wasn't the first gene therapy approved in the U.S. That milestone belongs to Spark Therapeutics' Luxturna (voretigene neparvovec), a treatment for...
While past FDA chiefs have joined drugmaker boards following their tenure, Gottlieb's move to Pfizer is both rapid and more high-profile than that of...
First-generation cell therapies, such as those developed by Novartis and Gilead, rely on immune cells collected from each individual patient. A painstaking manufacturing process...
Drugmakers want better designed, less expensive clinical trials. The demand is so great that contract research providers, often called CROs, are building out their...
Expectations for Evenity (romosozumab) are modest, and the rejection by the EMA is a "minor setback" for Amgen, according to RBC Capital Markets analyst...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...
